Suboptimal Neuromotor Development May Increase Genetic Risk for Schizophrenia
Nonoptimal infant neuromotor development was linked to genetic risk for schizophrenia, but not bipolar disorder.
Schizophrenia
Interleukin-6 Blockade, Low C-reactive Protein Levels May Increase Schizophrenia Risk
Specific inflammatory biomarkers may have an impact on the risk of developing schizophrenia.
Social Stigma May Negatively Impact Treatment Adherence in Schizophrenia
Poor adherence to antipsychotic treatment in schizophrenia may be attributable to socially negative representations of schizophrenia.
Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
Patients with schizophrenia, schizoaffective disorder, and psychotic bipolar disorder were examined for anticholinergic burden.
Depression, Schizophrenia Identified With Objective Blood Biomarker
NMDA receptor signaling is increased in patients with depression and reduced in those with schizophrenia.
Antipsychotic Polypharmacy Prevalent Despite Guidelines
Having schizophrenia and a length of stay of 90 days or more were the strongest predictors of polypharmacy.
Antipsychotics May Elevate Risk of Movement Disorders
The odd relationship may have more to do with the mental disorder than the drugs.
Excessive Activity in Genetic Variant May Underly Schizophrenia
Researchers uncovered a link between elevated levels of C4A protein, excessive synaptic pruning, and the development of schizophrenia.
Inhibitory Neuron Deficit May Contribute to Social Withdrawal in Schizophrenia
A mouse model of schizophrenia showed a significant decrease in inhibitory CA2 neurons.
Biotypes Highlight Unique Biological Manifestations of Psychosis
The unique biotypes may allow for more targeted treatments to be developed.
